Braftovi® (encorafenib) plus Mektovi® (binimetinib) – New indication
October 12, 2023 - Pfizer announced the FDA approval of Braftovi (encorafenib) plus Mektovi (binimetinib), for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.
Top